Skip to content

Aileron Acquires Lung Therapeutics

Acquisition of Lung Therapeutics and concurrent $18M private investment positions the company to advance first-in-class therapies for orphan pulmonary and fibrosis conditions.

Learn More

Developing novel medicines to provide better treatment options for patients with life-threatening pulmonary conditions

With its acquisition of Lung Therapeutics, Aileron is shifting its disease focus to advancing a pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis diseases. Lung Therapeutics’ lead clinical programs include LTI-03 for idiopathic pulmonary fibrosis (IPF) and LTI-01 for loculated pleural effusion (LPE).

LTI-03: A Pioneering Compound Treatment for IPF

IPF is a chronic lung disease characterized by progressive tissue scarring that prevents proper lung function.

LTI-03 operates through a novel mechanism of action by targeting healthy epithelial cells and profibrotic proteins. LTI-03 promotes the protection of lung epithelium while inhibiting fibroblast growth and expansion.

LTI-03 is currently being evaluated in a Phase 1b clinical trial in patients recently diagnosed with IPF.

LTI-01: First-in-Class Treatment for LPE

A pleural effusion is defined by the build-up of fluid in the pleural cavity, predominantly resulting from pneumonia. An LPE occurs when scar tissue forms in the pleural cavity, trapping the fluid and preventing drainage. LTI-01 is a proenzyme, or zymogen, designed to slowly activate in the pleural space and break up the scar tissue, allowing for drainage of the pleural effusion. The Company believes this unique mechanism can help efficacy and can provide dosing convenience and while avoiding significant bleeding side effects which can occur in off-label use of fibrinolytics for the treatment of LPE.

LTI-01 has been evaluated in Phase 1b and Phase 2 clinical trials in patients with infected, non-draining LPEs. LTI-01 has received Orphan Drug Designation in the US and EU for the treatment of empyemas and Fast Track Designation in the US.

Management Team

Board of Directors

Integrity is everyone’s responsibility at Aileron Therapeutics.

Submit a confidential and anonymous concern through our secure web form or hotline below:

SECURE WEB FORM     HOTLINE: 866-869-5217